Semax + Selank is a vendor blend of two Russian-developed research peptides. This page describes hypothesized areas of interest for each component and does not recommend use. Neither peptide is FDA-approved.
Overview
The appeal of the Semax + Selank blend is the idea of pairing a cognition- oriented peptide with an anxiety-oriented one. To discuss it honestly, the two components have to be considered separately, because that is where the research actually lives.
- Semax — studied mainly for cognitive and neuroprotective interest.
- Selank — studied mainly for anxiety-related interest.
- The blend itself has no dedicated studies.
Semax and cognitive interest
Semax is derived from a fragment of ACTH and has been studied as a nootropic. Research interest has centered on cognition, attention, and neuroprotection, with hypothesized links to brain-derived neurotrophic factor (BDNF).
- The interest is in cognitive support and neuroprotection, framed as investigational.
- Much of the supporting work is Russian and not widely replicated internationally.
- Cognitive claims should be read as hypothesized, not proven.
Selank and anxiety interest
Selank is a synthetic analog of the immunopeptide tuftsin and has been studied as an anxiolytic. Research interest has centered on anxiety, with hypothesized effects on GABAergic and serotonergic signaling.
- The interest is in reducing anxiety, framed as investigational.
- As with Semax, much of the evidence is Russian and not widely replicated.
- Anxiety-related claims should be read as hypothesized, not proven.
The combination question
The core honest point about this blend: pairing a cognition peptide with an anxiety peptide is a reasonable-sounding idea, but no controlled trials test the two together. Any claim of a combined or synergistic benefit is an extrapolation from two separate single-agent literatures.
Combining agents can just as easily produce overlapping or unpredictable effects as complementary ones. The blend's benefits are therefore best described as doubly hypothetical.
Evidence and caveats
Key caveats for the Semax + Selank blend:
- Neither component is FDA-approved in the United States.
- Component evidence is largely Russian with limited independent replication.
- The combination has no dedicated trials.
- Any combined benefit is extrapolated and should be treated as hypothesized.